CHRIS SAVILEActually the driving force behind their scientific achievements, NOT Facchini. They thank him for his contributions. Chris Savile to chief operations officer and the departures of Dr. Peter Facchini, chief scientific officer, and Dr. Jill Hagel, vice-president, applied science, effective immediately. "Chris's extensive scientific knowledge and proven business acumen will be a valuable addition to our executive leadership team," said Trevor Peters, president and chief executive officer. "Chris has played an integral part in the success Willow has achieved to date. He is the driving force behind our scientific achievements, including developing our state-of-the-art, high-throughput strain engineering laboratory in Mountain View, Calif., and negotiating key partnerships that will advance our business towards commercialization, including the recent strategic partnership with Albany Molecular Research Inc." Dr. Savile has been with Willow since April, 2019, in the role of vice-president, commercial operations. Prior to joining Willow, Dr. Savile worked in senior leadership roles at Intrexon Corp., a biotechnology company, and Codexis Inc., a protein engineering company. He is a highly experienced chemist, high-throughput assay scientist and protein engineer with a strong technical background. Dr. Savile has been the research and development leader on several programs that led to commercial manufacturing processes. He received his PhD in 2006 from McGill University. The company wishes to thank Dr. Facchini and Dr. Hagel for their contributions in developing Chris Savile to chief operations officer and the departures of Dr. Peter Facchini, chief scientific officer, and Dr. Jill Hagel, vice-president, applied science, effective immediately. "Chris's extensive scientific knowledge and proven business acumen will be a valuable addition to our executive leadership team," said Trevor Peters, president and chief executive officer. "Chris has played an integral part in the success Willow has achieved to date. He is the driving force behind our scientific achievements, including developing our state-of-the-art, high-throughput strain engineering laboratory in Mountain View, Calif., and negotiating key partnerships that will advance our business towards commercialization, including the recent strategic partnership with Albany Molecular Research Inc." Dr. Savile has been with Willow since April, 2019, in the role of vice-president, commercial operations. Prior to joining Willow, Dr. Savile worked in senior leadership roles at Intrexon Corp., a biotechnology company, and Codexis Inc., a protein engineering company. He is a highly experienced chemist, high-throughput assay scientist and protein engineer with a strong technical background. Dr. Savile has been the research and development leader on several programs that led to commercial manufacturing processes. He received his PhD in 2006 from McGill University. The company wishes to thank Dr. Facchini and Dr. Hagel for their contributions in developing Willow's proprietary cannabinoid-producing yeast strain and allowing the company to begin scale-up ahead of initial expectations. As the company moves into the scale-up phase of its operations, it has reallocated resources to more efficiently manage this process, resulting in a reduction in its Calgary-based head count. These changes are expected to drive annualized cost savings of $3-million and are not expected to impact Willow's ability to meet its expedited timeline to reach commercialization in the first half of 2021. About Willow Biosciences